Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hepatitis b vaccine (recombinant) (Keymen İlaç)
- Development stage
- Approved
- Lead developer
- KEYMEN
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
This recombinant hepatitis B vaccine, developed and marketed by Keymen İlaç Sanayi ve Ticaret, is a protein subunit vaccine designed to provide active immunity against the hepatitis B virus (HBV). The vaccine is produced using recombinant DNA technology, where the hepatitis B surface antigen (HBsAg) is expressed in yeast cells (*Saccharomyces cerevisiae*). Upon administration, the purified HBsAg protein acts as an immunogen, stimulating the host's immune system to produce protective anti-HBs antibodies. It is indicated for the prevention of infection caused by all known subtypes of HBV in adults. The formulation is typically a suspension for intramuscular injection and includes an aluminum-based adjuvant to enhance the immune response.
- Brand names
- Adult Hepatitis B Vaccine rDNAHepatitis B Vaccine (rDNA)
- Other names
- Hepatitis B Vaccine (recombinant, adult)Recombinant Hepatitis B Vaccine
02
Targets
HBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on hepatitis b vaccine (recombinant) (Keymen İlaç).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hepatitis b vaccine (recombinant) (Keymen İlaç).